Casebia Therapeutics, Bayer and CRISPR Therapeutics’ joint venture, began operations in Cambridge, MA. The JV, created in December 2015, aims to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. Recently named, Casebia is a UK entity with its primary research base in Cambridge. Casebia has access to gene-editing technology from CRISPR Therapeutics in specific disease areas, as well as access to protein engineeri...